Sandoz secures EC approval for denosumab biosimilars Wyost and Jubbonti, Europe's first for Xgeva and Prolia references.
Sandoz, a major player in generic and biosimilar drugs, has secured European Commission (EC) approval for its denosumab biosimilars, Wyost and Jubbonti. These are the first biosimilar versions of reference medicines Xgeva and Prolia in Europe. Wyost is for cancer-related bone disease treatment, while Jubbonti is for osteoporosis. This approval marks a key milestone in Sandoz's growth strategy and plans to launch these products from November 2025 onwards.
May 21, 2024
18 Articles